Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175220 | 0.82 | KMT2A (0.33) | KIF11KMT2ASMN1; SMN2NR3C1 | |
| SCHEMBL5467643 | 0.80 | NR3C1 (0.41) | KIF11KMT2ASMN1; SMN2NR3C1 | |
| SCHEMBL5173756 | 0.75 | KMT2A (0.35) | KIF11KMT2ALDHASMN1; SMN2 | |
| SCHEMBL28768718 | 0.73 | NR3C1 (0.35) | KIF11KMT2ALDHASMN1; SMN2NR3C1 | |
| SCHEMBL5467686 | 0.73 | NR3C1 (0.33) | KMT2ANR3C1 | |
| SCHEMBL5173687 | 0.72 | KMT2A (0.35) | KIF11KMT2ALDHASMN1; SMN2 | |
| SCHEMBL3427001 | 0.71 | AKR1B1 (0.32) | KMT2A | |
| SCHEMBL3428327 | 0.68 | AKR1B1 (0.46) | KIF11 | |
| SCHEMBL3177133 | 0.68 | ITGB2 (0.41) | KMT2ALDHASMN1; SMN2 | |
| SCHEMBL22426762 | 0.67 | ITGB2 (0.40) | KMT2ALDHASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101160305-A | Substituted chroman derivatives, method for the production and the use thereof in the form of antiphlogistics | SCHERING AG (DE) | 2008-04-09 | — | — | CN | disclosed |
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | KIF11 4771/4885KMT2A 4398/4885LDHA 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.